Aerie Pharmaceuticals

A person in a grey sweater rubs their eyes Dry eye disease can cause a wide range of symptoms including pain blurry vision
Biotech

Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins

The lead candidate in the acquired pipeline met the primary phase 3 endpoint, positioning Alcon to file for FDA approval in the middle of the year.
Nick Paul Taylor Jan 10, 2024 5:40am
Illustration connected puzzle pieces with the acronym MA

Alcon swoops on Aerie, striking $770M buyout to expand pipeline

Aug 23, 2022 7:45am
Parachute

Novartis loses cell, gene leader, digital exec—Chutes & Ladders

Sep 24, 2021 9:30am
exit

Aerie CEO exits days after downplaying midphase eye disease flop

Sep 21, 2021 8:20am
missed the mark

Aerie fails its primary endpoint in eye disease test

Sep 16, 2021 4:42am
Parachute

Aerie taps former Allergan exec as new VP—Chutes & Ladders

Feb 7, 2020 9:30am